Vycor Medical, Inc. (OTCQB-VYCO) reported revenue of $414,895 for the three months ended September 30, 2026, a 19% decrease from the $513,792 recorded in the same period of 2025, according to financial results announced through NEWMEDIAWIRE. For the nine months ended September 30, 2026, company revenue was $1,291,699, down 11% from $1,446,523 a year earlier.
The Boca Raton, Florida-based company operates two business units. Vycor Medical produces the ViewSite Brain Access System (VBAS), a minimally invasive neurosurgical device used to access brain lesions, while NovaVision offers therapy programs intended to help patients recover from visual disorders following stroke or other brain injury.
Revenue from the Vycor Medical division fell 18% to $402,048 for the third quarter and 11% to $1,243,713 for the nine-month period. The company said it experienced higher than normal U.S. sales during the 2025 period from new hospitals and bulk orders from some existing hospitals, which largely accounts for the decrease, offset by increased international sales for the three-month period and a slight decrease over the nine months. Vycor noted that international sales can often be lumpy, with large orders sometimes falling in different quarters.
The NovaVision division, which remains in development, generated revenue of $12,847 for the third quarter, a 41% increase over the 2025 period, and $47,986 for the nine months, an 11% increase. Gross profit for the quarter was $353,017, a 22% decrease, generating a margin of 85% compared with 88% a year earlier. Nine-month gross profit was $1,072,615, a 12% decrease, with a margin of 83% compared with 85%.
Operating profit for the three months was $27,424 compared with $32,085 in 2025, while nine-month operating profit rose to $80,083 from $70,425. Non-GAAP operating profit was $43,011 for the quarter compared with $60,162 a year earlier, and $125,751 for the nine months compared with $166,262. The company reported a GAAP net loss available to common stockholders of $(161,447), or $(0.00) per share, for the quarter and $(325,812), or $(0.01) per share, for the nine months. Management uses non-GAAP measures that exclude non-cash depreciation of purchased assets and non-cash stock-based compensation to evaluate continuing operations, though it notes such measures have limitations and should not be considered a substitute for GAAP results.
During 2026 to date, four new peer-reviewed studies were published on VBAS, bringing the total published peer-reviewed clinical papers to 54, with an additional 14 other clinical papers. The studies addressed a complex pediatric tumor case, a 23-patient retrospective comparison of VBAS with traditional blade retractors that highlighted significantly fewer new neurological deficits, a 29-patient study of minimally invasive resection of posterior fossa metastases, and two Japanese cases of intracerebral hemorrhage evacuation using VBAS with an exoscope. For an overview of the device, the company offers a VBAS Video, and additional information is available at www.vycormedical.com and www.vycorvbas.com.
The results matter to investors and clinicians because they show a device business whose top line is sensitive to hospital purchasing timing, even as its installed base has grown to more than 350 U.S. hospitals and numerous international markets. NovaVision's growth is notable, but the company states the therapies still require significant development to address their market potential. A NovaVision Video and further details at www.novavision.com outline the division's Visual Restoration Therapy.
